Nerve stimulation device maker Mobia Medical files for a $100 million IPO
May 8, 2026 News
Nerve stimulation device maker Mobia Medical prices IPO at $15, the midpoint of the range
Mobia Medical, which sells a nerve stimulation implant for chronic ischemic stroke, raised $150 million by offering 10 million shares at $15, within the $14 to $16 range. At pricing, the company commands a fully diluted market value of $549 million.
May 4, 2026 News
Nerve stimulation device maker Mobia Medical sets terms for $150 million IPO, pricing this week
Mobia Medical, which sells a nerve stimulation device for chronic ischemic stroke, announced terms for its IPO on Monday.
The Austin, TX-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16.
IPO Overview
Mobia Medical, which sells a nerve stimulation device for chronic ischemic stroke, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Mobia’s Vivistim Paired Vagus Nerve Stimulation System is the first and only clinically-validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. The system includes an implanted pulse generator and lead that deliver stimulation during functional movement in order to increase neuroplasticity and durably restore motor function. Management estimates that there are over four million chronic ischemic stroke survivors, of which one million have the health, cognition, and motivation to participate in post-stroke therapy, representing a $30 billion opportunity based on the system’s price.
The Austin, TX-based company was founded in 2007 and booked $32 million in revenue for the 12 months ended December 31, 2025. It plans to list under the symbol MOBI. Mobia Medical filed confidentially on January 21, 2026. BofA Securities, J.P. Morgan, and Goldman Sachs are the joint bookrunners on the deal. No pricing terms were disclosed.
About the Company
We are a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Our Vivistim Paired Vagus Nerve Stimulation （Paired VNS） System is the first and only clinically-validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Stroke is one of the leading causes of long-term disability in the United States. While advancements in acute stroke care over the past decade have significantly reduced mortality, innovation for chronic stroke recovery has lagged, resulting in a growing number of stroke survivors living with meaningful impairments. Our breakthrough Vivistim Paired VNS System （Vivistim System） addresses this unmet need. The Vivistim System includes an implanted pulse generator and lead that deliver stimulation to the vagus nerve when activated. During treatment （Vivistim Therapy）， intentional bursts of stimulation are delivered during functional movement to increase neuroplasticity and durably restore motor function. Clinical data has demonstrated that Vivistim Therapy delivers meaningful improvements in upper limb function, which can help stroke survivors regain critical capabilities and independence and restore quality of life, regardless of the time elapsed since the patient’s stroke.